Lessons learned from the Western Australian experience with mesothelioma



Similar documents
Asbestos Health Risks. Dr Andrew Pengilley Acting Chief Health Officer

Asbestos: health effects and risk. Peter Franklin Senior Scientific Officer, EHD Senior Research Fellow, UWA

Mesothelioma in Australia: Incidence (1982 to 2013) and Mortality (1997 to 2012)

MESOTHELIOMA IN AUSTRALIA INCIDENCE 1982 TO 2008 MORTALITY 1997 TO 2007

MESOTHELIOMA IN AUSTRALIA INCIDENCE 1982 TO 2009 MORTALITY 1997 TO 2011

Table 2.4. Summary of design and findings from mesothelioma case-control studies

Mesothelioma risk after 40 years since first exposure to asbestos: a pooled analysis

Asbestos Related Diseases

quick history of asbestos

Malignant Mesothelioma

Malignant Mesothelioma

Asbestos Diseases. What Is Asbestos?

Asbestos Related Diseases. Asbestosis Mesothelioma Lung Cancer Pleural Disease. connecting raising awareness supporting advocating

Summary of treatment benefits

Survey of Mesothelioma Associated with Asbestos Exposure in Japan

THE AUSTRALIAN MESOTHELIOMA REGISTRY (AMR)

NISG Asbestos. Caroline Kirton

Asbestos risks, safety and its role in lung disease

National Strategic Plan for Asbestos Awareness and Management

Occupational respiratory diseases due to Asbestos. Dirk Dahmann, IGF, Bochum

ASBESTOS DISEASES. Dr Alastair Robertson

L Lang-Lazdunski, A Bille, S Marshall, R Lal, D Landau, J Spicer

WA Asbestos Review Program

Scientific Update on Safe Use of Asbestos. Robert P. Nolan, PhD International Environmental Research Foundation New York, New York

B enign pleural disease (discrete plaques and pleural

Asbestos and the diseases it causes

Mesothelioma: Questions and Answers

EFFECT OF CHILDREN'S AGE AND LIFE EXPECTATION ON MESOTHELIOMA RISK 1

ASBESTOS MANAGEMENT REVIEW

PATTERNS OF MORTALITY IN ASBESTOS FACTORY WORKERS IN LONDON*

Malignant Mesothelioma in Australia,

Asbestos-Related Cancer Research and Prevention

ASBESTOS SAFETY & ERADICATION AGENCY CONFERENCE NOVEMBER 2014

Malignant Mesothelioma: an Update

Cancer incidence among women and girls environmentally and occupationally exposed to blue asbestos at Wittenoom, Western Australia

Asbestos and Mesothelioma a briefing document for the Metropolitan Police

Na#onal Asbestos Forum 2013: Advance in Medical Research on Asbestos- Related Diseases

Francine Lortie-Monette, MD, MSc, CSPQ, MBA Department of Epidemiology and Biostatistics University of Western Ontario 2003

The Belgian Asbestos Fund

Efficiently Maintaining Commercial Buildings. Asbestos Awareness

Malignant Mesothelioma State of the Art

Estimation of the Number of Lung Cancer Cases Attributable to Asbestos Exposure

ASBESTOS MANAGEMENT IN THE MIDDLE EAST. Charles Faulkner Asbestos Risk Management Consultant TEP Environmental Consultants

Asbestos related cancers

(1) Comparison of studies with different follow-up periods

Clinical cases in Malignant Pleural Mesothelioma: Adherence to the ESMO Clinical Practice Guidelines

Master Builders Australia NATIONAL ASBESTOS MANAGEMENT CONTROL AND REMOVAL POLICY

Current Usage and Health Significance of the Modern Use of Chrysotile Products: Review of Recently Published Evidence

Changing Trends in Mesothelioma Incidence. Hans Weill, M.D. Professor of Medicine Emeritus Tulane University Medical Center

MONTH OF ISSUE: October 2011 TO: MANAGERS, SUPERVISORS, GENERAL FOREMEN & CREWS SUBJECT: Asbestos Alert

Asbestos Review Program Update

NHS Barking and Dagenham Briefing on disease linked to Asbestos in Barking & Dagenham

Mesothelioma. 1. Introduction. 1.1 General Information and Aetiology

FIGHTING FOR YOU. Asbestos and dust diseases

Executive summary. Background

Asbestos Diseases Society of Victoria: Submission to the Asbestos Management Review

Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma

Workers Compensation and Trust Fund Claims for Mesothelioma

Introduction Objective Methods Results Conclusion

Asbestos : Revising the overall summary analysis of cohorts Approach 2

Lung cancer and asbestos

Toxicity of Amphibole Asbestos

Asbestos. Part 1. Overview. What is asbestos? Prepared by: Penny Digby Principal Adviser (Occupational Health) Workplace Health and Safety Queensland

BY THE NUMBERS: THE FUTURE OF MESOTHELIOMA IN AMERICA

Mesothelioma , The Patient Education Institute, Inc. ocft0101 Last reviewed: 03/21/2013 1

Rare Thoracic Tumours

Asbestos - Frequently Asked Questions

INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER Prospective Mesothelioma Staging Project

Preparing an estimate of the national pattern of exposure to asbestos in cases of malignant mesothelioma

Griffith University - Case for Support. Mesothelioma Research Program

Frequently asked questions

Epidemiological insight into occupational causes of respiratory cancers

Asbestos Management and Control Policy for Government Buildings

Compensation for Environmental and Domestic Exposure Cases

Mesothelioma among shipyard workers in Monfalcone, Italy

ASBESTOS. Know what it is and how you can protect yourself. environmental affairs Department: Environmental Affairs REPUBLIC OF SOUTH AFRICA

Actuarial projections for mesothelioma: an epidemiological perspective Mark Clements, Geoffrey Berry and Jill Shi

Clinical Indications and Results Following Chest Wall Resection

SPONTANEOUS MESOTHELIOMA DATA: AN INTERPRETATION. Robin Howie, Robin Howie Associates, Edinburgh.

australian mesothelioma registry

Asbestos and Mesothelioma in Ontario

THE HEALTH OUTCOMES OF WOMEN EXPOSED TO BLUE ASBESTOS AT WITTENOOM

Asbestos related health risks

australian mesothelioma registry

Malignant Mesothelioma Among Employees of a Connecticut Factory that Manufactured Friction Materials Using Chrysotile Asbestos

Editorial 9 March 2012

Before you start DIY or refurbishments in your home THINK!

Transcript for Asbestos Information for the Community

Occupational Disease Fatalities Accepted by the Workers Compensation Board

How To Prevent Asbestos Related Diseases

Mesothelioma Trends as Predictors of the Asbestos- Related Lung Cancer Burden

In the course of this work we observed:

Frequently Asked Questions. What is asbestos? 2. How is asbestos harmful? 2. What illnesses does asbestos cause? 3

UNIVERSITY OF LEICESTER ESTATES & FACILITIES MANAGEMENT DIVISION ASBESTOS MANAGEMENT PLAN

Sir William Osler: Listen to the patient; the patient tells you everything.

The asbestos crisis Why Britain needs an eradication law

The asbestos crisis. Why Britain needs an eradication Law. Background. Levels of mortality

australian mesothelioma registry

Descriptive Study of Mesothelioma in the Australian Capital Territory

Transcription:

Lessons learned from the Western Australian experience with mesothelioma Alison Reid, Western Australian Institute for Medical Research In partnership with Nick de Klerk, Nola Olsen, Jan Sleith, Geoffrey Berry, Bill Musk Peter Franklin, Patrick Aboagye-Sarfo, Latha Samuel And many others

Outline of this talk Discuss sources of asbestos exposure Assess the long term risk of developing mesothelioma after being exposed to asbestos Examine mesothelioma treatment and survival at a population level

Malignant mesothelioma Cancer of the pleura or peritoneum Very rare Caused by asbestos, erionite, radiation Painful, debilitating, no treatment, no cure Median survival 9 months Universally fatal Risk of disease increases the longer time passes after exposure

Wittenoom Asbestos mine and mill 7,000 employees, 1943 1966 Australian Blue Asbestos Company (ABA) 5,000 residents in township, not employed by ABA Tailings from mine distributed around the township Only mined crocidolite (blue asbestos)

Western Australian Mesothelioma Registry Cancer is a notifiable disease in Western Australia All incident cases of mesothelioma are reviewed by a committee to document dates and methods of diagnosis, site, treatment received, and date of death, as well as asbestos exposure status

WA Mesothelioma (all types) - 3 year moving average 120 110 100 90 Males Females Rate per million (age 20+) 80 70 60 50 40 30 20 10 0 1970 1975 1980 1985 1990 1995 2000 2005 Year of diagnosis

Asbestos exposure - WAMR 90 80 Number of cases 70 60 50 40 30 None Unknown Other residential Wittenoom residents Other occupational Wittenoom workers 20 10 0 1971 1976 1981 1986 1991 1996 2001 Year of diagnosis

Three waves of malignant mesothelioma First wave: workers in mining and milling of asbestos and manufacture of asbestos products Second wave: persons who used asbestos products e.g. insulators, carpenters, Third wave: In place exposure e.g. exposure from asbestos in buildings..do-it-yourself renovators

Home renovation Post WWII asbestos was used extensively as a building product in homes. Up until 1960 s ~25% of homes clad with asbestos cement sheets Asbestos has not been used in domestic building materials since the (late) 1980s Little data on number of homes with asbestos ACT: asbestos in 62.9% of surveyed homes 70% homes built <1965 but 1% built >1984

Trend - All cases MM cases 1960-2008 Number of cases 250 200 150 100 50 Witt workers Other workers Witt res Other res DIY No known Unknown 0 5-year periods In the period 2005 08 DIY 2 nd most common exposure category

Males MM cases for males, 1960-2008 Number of cases 250 200 150 100 50 Witt workers Other workers Witt res Other res DIY No known Unknown 0 5-year periods In the period 2005 08 DIY cases account for ~8.5% of total

Females MM cases for females, 1960-2008 Number of cases 25 20 15 10 5 0 Witt workers Other workers Witt res Other res DIY No known Unknown 5-year periods In the period 2005 08 DIY cases account for ~36% of total

Does mesothelioma risk decline after 40 years since first exposure? A pooled analysis Mesothelioma risk increases proportionally to 3 rd or 4 th power of time since first exposed to asbestos No clear understanding of long term risk of mesothelioma Few cohort studies have long term follow up Suggestion pleural mesothelioma risk may decline after 40 years since first exposure Clearance of fibres from the lung Susceptibility

Methods Six Occupational Cohorts Wittenoom miners and millers, Australia Eternit asbestos cement factory workers, Italy Stagna, Cittadella and Vicenza railway car construction and renovation workers, Italy Amosite factory workers Italy Two Environmentally exposed cohorts Wittenoom residents Eternit wives

Data manipulation Renamed/coded variables so data could fit together Combined all cohorts Data split into o One year increments of age o Five year increments of calendar period o One year increments of time since first exposure Pleural/peritoneal cases matched with controls on age and calendar period Each case matched to a maximum of 150 controls Separate datasets for peritoneal and pleural mesothelioma

Cohort Results - Description of cohorts Wittenoom Workers N 16,279 (m) 5,769 (f) 6,489 (m) 421 (f) 2,206 (m) 2, 615 (f) 2,657 (m) 777 (f) Definition Period of operation Type of asbestos Crocidolite mine and mill workers 1937-1966 Crocidolite Wittenoom Residents Lived in Wittenoom for more than 1937-1992 Crocidolite one month Eternit Workers Asbestos cement factory workers 1907-1986 Mixed includes (Casale Monferrato) amphibole Eternit Wives 1,779 (f) Wives of eternit factory workers 1921-1986 Mixed includes amphibole Amosite factory 248 (m) Amosite factory workers 1919-1978 Amosite (Molina di Ledro) 161 (f) Stagna 1,847 (m) Railway car construction and 1956-1982 Mixed includes 6 (f) renovation workers amphibole Cittadella 1,125 (m) Railway car construction and 1956-1989 Mixed includes 10 (f) renovation workers amphibole Vicenza 1,706 (m) Railway car construction and 1956-1988 Mixed includes renovation workers amphibole

Cohort Mesotheliomas Pleural N=494 (m) N=155 (f) N=649 Peritoneal N=112 (m) N=30 (f) N=142 Median time since first exposure (pleural mm) Years (IQR) Wittenoom Workers 276 (m) 14 (f) 49 (m) 35.6 (28.9-41.7) Wittenoom Residents 47 (m) 43 (f) 5 (m) 1 (f) 41.2 (35.9 45.7) Eternit Workers 123 (m) 54 (f) 49 (m) 24 (f) 40.6 (32.7 48.5) Eternit Wives 36 (f) 3 (f) 42.2 (35.8 47.8) Amosite factory 3 (m) 7 (f) 1(m) 2 (f) 47.2 (40.3 56.3) Stagna 33 (m) 1 (f) 3 (m) 42.5 (33.1 50.2) Cittadella 4 (m) 1 (m) 39.4 (31.0 46.1) Vicenza 8 (m) 4 (m) 43.4 (34.8 46.2)

Rate of pleural mesothelioma and time since first exposure, 648 cases each matched with 150 controls Log rate 0.0-0.5-1.0-1.5-2.0-2.5-3.0-3.5-4.0-4.5 10 100 Years since first exposure (log) timesince

Log rate Rate of peritoneal mesothelioma and time since first exposure, 149 cases each matched with 150 controls 1 0.5 0-0.5-1 -1.5-2 -2.5-3 -3.5-4 10 100 Years since first exposure (log) timesince

Mesothelioma treatment and survival Attracts increasing medical interventions and escalating health care costs as novel treatments are tried What is the evidence for success in a total population?

Since; First clinical trial of gemcitabine and cisplatinum showed partial response rates of 30-40% and similar stable disease rates and the demonstration of significantly prolonged survival with pemetrexed and cisplatinum more patients are submitting to active treatment regimes. Trimodality therapy with radical pleuropneumonectomy, radiotherapy and chemotherapy still attracts some people with "early" disease. Gene therapy and immunotherapy trials are common in conference proceedings and reports. Some highly selected groups show longer survival

Change in survival over time 0.00 0.25 0.50 0.75 1.00 0 6 12 18 24 30 36 42 48 54 60 Months after diagnosis 1960-79 1980s 1990s 2000s

Survival by site of mesothelioma 0.00 0.25 0.50 0.75 1.00 0 6 12 18 24 30 36 42 48 54 60 Months after diagnosis Pleural unsp Left pleura Peritoneal Right pleural

Survival by histology 0.00 0.25 0.50 0.75 1.00 0 6 12 18 24 30 36 42 48 54 60 Months after diagnosis Site unsp Epithelioid Sarcomatoid Biphasic

Improved survival for women 0.00 0.25 0.50 0.75 1.00 0 6 12 18 24 30 36 42 48 54 60 Months after diagnosis Male Female

Survival 0.25.5.75 1 0 6 12 18 24 30 36 42 48 54 60 Months after diagnosis 50y f epithelial pleural 70y m sarcomatous peritoneal

Conclusions Despite increasing resources and treatment costs of malignant mesothelioma there have been only modest improvements in survival over the past 40 years. Prevention of exposure to asbestos still remains the urgent priority for mesothelioma prevention. Prevention includes: (i) banning production manufacture and use; (ii) subsidised and supervised removal and disposal; (iii) protection from known sources of exposure.